RNAZ - TransCode Therapeutics Future Price to Earnings
The efficiency of RNA delivery into tumors and molecular stability determine the success of TransCode Therapeutics (RNAZ), as evidenced by the company's forward P/E ratio, which is currently fixed at 0.00. High expenditures in the absence of profit necessitate rigorous management of clinical trials. The development of a precision targeting system for metastases transforms this biotech firm into a key hub for combating incurable forms of cancer.
TransCode (RNAZ) - metric breakdowns and financial figures
- stock value and consensus price forecast:
- market capitalization statistics:
- balance sheet equity data:
- debt and liquidity details:
Total Debt to Capital TransCode Therapeutics|RNAZ - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital TransCode Therapeutics|RNAZ - Company Cumulative Debt|Debt to Book Value TransCode Therapeutics Inc.|RNAZ - Company Long-Term Loans and Borrowings|Company Current Liabilities TransCode Therapeutics|Quick Ratio transcodetherapeutics.com
- earnings and market ratios statistics:
RNAZ - Final Profit|Projected Future Earnings TransCode Therapeutics|RNAZ - Market Cap to Earnings|Future Price to Earnings TransCode Therapeutics|RNAZ - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple TransCode Therapeutics Inc.|RNAZ - Operating profit EBITDA|Earnings per share for the last twelve months TransCode Therapeutics|RNAZ - Earnings per one share for the last 12 months|Quarterly EPS earnings growth transcodetherapeutics.com|RNAZ - Earnings per share growth rate in current year|Expected earnings per share growth for next year TransCode Therapeutics
Analysis of all company metrics:TransCode Therapeutics, Inc. RNAZ
This indicator is calculated as the ratio of current market capitalization to projected net income, allowing for an assessment of the business's future value considering expected operating expenses. The trend of the calculated forward P/E for TransCode Therapeutics (RNAZ) reflects the company's ability to balance RNA therapy environmental safety costs and testing ethics with final profitability, signaling entry points or risks of inflationary pressure to the investor.
Direct competitors
Future Price to Earnings Tempus Labs (TEM)|Qiagen NV - Price to Future Earnings Ratio|Future Price to Earnings Ionis Pharma IONS|Market Cap to Projected Earnings Repligen Inc. (RGEN)|Avidity Biosciences - Forward P/E Multiple|crisprtx.com (CRSP) - Projected Price to Earnings|GeneDx (WGS) - Future Price to Earnings|Projected Price to Earnings Ratio Ultragenyx Pharmaceutical Inc. (RARE)|BEAM (Beam Therapeutics Corp) - Forward P/E Multiple|Price to Future Earnings Ratio SRPT (Sarepta Corp)|Forward P/E Multiple TWST|TXG - Projected Price to Earnings Ratio|Intellia Therapeutics, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple STOK|BLFS: Projected Price to Earnings|Wave Pharma - Market Cap to Future Earnings Ratio|MAZE: Forward P/E Multiple|sionnatx.com - Future Price to Earnings Multiple|PRME (Prime Medicine) - Forward P/E Multiple|Projected Price to Earnings Ratio Taysha Gene Therapies Inc TSHA|Future Price to Earnings uniQure Corp (QURE)|MGTX (MeiraGTx Corp) - Future Price to Earnings Multiple|Forward P/E Multiple RGNX (REGENXBIO Inc.)|Forward P/E Multiple solidbio.com SLDB|OCGN - Future Price to Earnings|Price to Expected Earnings Ratio PACB|BNTC: Forward P/E Multiple|Projected Price to Earnings Ratio Design Corp (DSGN)|Projected Price to Earnings RCKT|Forward P/E Multiple 4dmoleculartherapeutics.com|Projected Price to Earnings LXEO (Lexeo Therapeutics)|Market Cap to Future Earnings Ratio KRRO|Forward P/E Multiple EDIT (Editas)|Market Cap to Projected Earnings Silence Therapeutics Corp (SLN)|ProQR Therapeutics NV - Forward P/E Multiple|Codexis, Inc. (CDXS) - Projected Price to Earnings|Sangamo Therapeutics, Inc. (SGMO) - Future Price to Earnings|NAUT - Market Cap to Projected Earnings|Future Price to Earnings Metagenomi, Inc|DTIL: Future Price to Earnings Multiple|Future Price to Earnings Generation Bio Co. (GBIO)|boundlessbio.com - Price to Future Earnings Ratio|Forward P/E Multiple XCUR (Exicure)|Forward P/E Multiple Imunon Inc IMNN|PHIO: Projected Price to Earnings|Price to Expected Earnings Ratio MBIO|BNGO: Forward P/E Multiple|Price to Future Earnings Ratio APDN|Future Price to Earnings bluebird bio|Price to Future Earnings Ratio IPA (ImmunoPrecise)|Forward P/E Multiple OMGA|Forward P/E Multiple Singular Genomics Corp (OMIC)|Regulus Therapeutics - Projected Price to Earnings|Market Cap to Future Earnings Ratio SYRS (syros.com)|TBIO - Future Price to Earnings|Future Price to Earnings Multiple TCON (TRACON Pharmaceuticals Inc.)|UBX: Forward P/E Multiple
